Subcutaneous · GLP-1 / GIP dual
NNC0519-0130
11 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
11
Active
1
Recruiting
1
Completed
10
Sites
274
Countries
20
Endpoints
91
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
8
Phase 2
3
Trials by status
Recruiting
1
Completed
10
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
46
Weight & body composition
15
Cardiometabolic biomarkers
14
Glycemic / diabetes
7
Renal / kidney
5
Patient-reported / QoL
4
Most-measured metrics
Top 20 metrics across this asset's endpoints
AUC₀–∞Safety/PK
15
Treatment-emergent AEs (any)Safety/PK
14
CmaxSafety/PK
10
HbA1c, changeGlycemic
4
Plasma concentration (steady state)Safety/PK
4
Body weight, % changeWeight
3
Waist circumference, changeWeight
3
Systolic BP, changeBiomarker
3
uACR, changeRenal
3
IWQOL-Lite physicalPRO/QoL
3
Body weight, absolute change (kg)Weight
2
Fasting glucose, changeGlycemic
2
hs-CRP, changeBiomarker
2
Total cholesterol, changeBiomarker
2
HDL-C, changeBiomarker
2
LDL-C, changeBiomarker
2
Triglycerides, changeBiomarker
2
eGFR, changeRenal
2
≥5% weight-loss respondersWeight
2
≥10% weight-loss respondersWeight
2
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
11 of 11